Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Roth

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
RMD Open|September 17, 2021
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparisonHermine I Brunner, Carlos Abud-Mendoza, Masaaki Mori, et al.
Leukemia & Lymphoma|August 12, 2023
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with <i>RARA</i> gene overexpressionEytan M Stein, Stephane de Botton, Thomas Cluzeau, et al.
Annals of the Rheumatic Diseases|October 5, 2022
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reportsMichelle Petri, Helain Landy, Megan E B Clowse, et al.
JCI Insight|December 8, 2022
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndromeXavier Mariette, Francesca Barone, Chiara Baldini, et al.
Rheumatology (Oxford, England)|May 22, 2024
Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosusEline J Arends, Mihaela Zlei, Christopher M Tipton, et al.
Arthritis Care & Research|April 19, 2022
Impact of Belimumab on Organ Damage in Systemic Lupus ErythematosusMurray B Urowitz, Cynthia Aranow, Yumi Asukai, et al.
Environmental Science & Technology|January 10, 2023
Contaminant Exposure and Transport from Three Potential Reuse Waters within a Single WatershedJason R Masoner, Dana W Kolpin, Isabelle M Cozzarelli, et al.
Annals of the Rheumatic Diseases|August 19, 2024
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE studyCynthia Aranow, Cornelia F Allaart, Zahir Amoura, et al.
Environment International|December 21, 2022
Bottled water contaminant exposures and potential human effectsPaul M Bradley, Kristin M Romanok, Kelly L Smalling, et al.
Annals of the Rheumatic Diseases|July 24, 2020
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trialHermine I Brunner, Carlos Abud-Mendoza, Diego O Viola, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
RMD Open|September 17, 2021
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparisonHermine I Brunner, Carlos Abud-Mendoza, Masaaki Mori, et al.
Leukemia & Lymphoma|August 12, 2023
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with <i>RARA</i> gene overexpressionEytan M Stein, Stephane de Botton, Thomas Cluzeau, et al.
Annals of the Rheumatic Diseases|October 5, 2022
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reportsMichelle Petri, Helain Landy, Megan E B Clowse, et al.
JCI Insight|December 8, 2022
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndromeXavier Mariette, Francesca Barone, Chiara Baldini, et al.
Rheumatology (Oxford, England)|May 22, 2024
Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosusEline J Arends, Mihaela Zlei, Christopher M Tipton, et al.
Arthritis Care & Research|April 19, 2022
Impact of Belimumab on Organ Damage in Systemic Lupus ErythematosusMurray B Urowitz, Cynthia Aranow, Yumi Asukai, et al.
Environmental Science & Technology|January 10, 2023
Contaminant Exposure and Transport from Three Potential Reuse Waters within a Single WatershedJason R Masoner, Dana W Kolpin, Isabelle M Cozzarelli, et al.
Annals of the Rheumatic Diseases|August 19, 2024
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE studyCynthia Aranow, Cornelia F Allaart, Zahir Amoura, et al.
Environment International|December 21, 2022
Bottled water contaminant exposures and potential human effectsPaul M Bradley, Kristin M Romanok, Kelly L Smalling, et al.
Annals of the Rheumatic Diseases|July 24, 2020
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trialHermine I Brunner, Carlos Abud-Mendoza, Diego O Viola, et al.
Pageof 6